For direct compression of dinotefuran in veterinary oral tablets, the API lot is pre-screened through a 500 µm sieve and dry-blended with microcrystalline cellulose, lactose monohydrate, crospovidone, colloidal silicon dioxide, and sodium stearyl fumarate in a tumble blender at 12 rpm for 15 min at 60% of nominal capacity. Dinotefuran is a nitroguanidine neonicotinoid with a molecular weight of 202.21 g/mol, water solubility of 39.8 g/L at 20 °C, and log Pow of −0.549. The high aqueous solubility shifts the critical quality risk away from dissolution and toward physical segregation, punch filming, and moisture uptake during direct compression. A starting core formula for direct compression may be prepared with API 25.0 wt%, microcrystalline cellulose 50.5 wt%, lactose monohydrate 18.0 wt%, crospovidone 4.0 wt%, colloidal silicon dioxide 0.5 wt%, and sodium stearyl fumarate 2.0 wt%; the active ratio is adjusted to the approved dose and tablet mass because no fixed pharmacopoeial ratio exists for dinotefuran across all jurisdictions. The pre-screened blend is compressed on a rotary press equipped with precompression rollers. Precompression force is held at 2–5 kN, main compression force at 8–18 kN, and turret speed up to 60 rpm for a 200 mg core; higher forces may induce capping and lamination. If the relative humidity in the compression suite exceeds 60%, pre-drying of the API and excipients is required, and the run is paused for moisture checks at intervals of 30 min.

Finished tablet cores are tested for weight variation and content uniformity by USP <905> with an acceptance value of ≤15.0, disintegration by USP <701> for immediate-release tablets, and dissolution by USP <711> using a validated medium because no harmonized monograph specifies a single medium for this active. Residual solvents are controlled by USP <467> and elemental impurities by ICH Q3D. Coating is performed in a perforated pan coater with an HPMC-based film system at 3–4% weight gain, inlet air 60–70 °C, product temperature 38–42 °C, and pan speed scaled to prevent edge wear. The coated tablets are packed in aluminium/aluminium blisters when moisture protection is specified. The terminal product is a film-coated immediate-release oral tablet released on assay, uniformity, dissolution, and water content.

What Changes When Dinotefuran Is Wet-Granulated into Capsule Fill?

Wet granulation is selected when the capsule fill must maintain uniform granule density and flow on a dosing-disc or tamping-pin filling machine. A high-shear granulator is charged with API 20.0 wt%, lactose monohydrate 59.5 wt%, pregelatinized starch 10.0 wt%, and croscarmellose sodium 5.0 wt%. A binder solution of povidone K30 at 4.0 wt% in purified water is sprayed during granulation; endpoint is controlled by impeller power consumption rather than fixed time, with impeller speed 250–350 rpm and chopper speed 1,200–1,800 rpm. The wet mass is discharged at a loss-on-drying of 8–12%, dried in a fluid-bed dryer at inlet air 55–65 °C to a final LOD of 1.5–2.5%, and milled through a 0.8 mm screen. The dried granulate is blended with colloidal silicon dioxide 0.5 wt% and magnesium stearate 1.0 wt% before encapsulation.

Encapsulation is run on a tamping-pin machine at 25,000–75,000 capsules/hour, depending on capsule size and powder flow. Capsule size is selected by fill weight; a size 3 or size 4 HPMC capsule is common for veterinary products in the 80 mg to 180 mg fill weight range, but the specific dose governs final fill. Uniformity of dosage units is tested by USP <905>, disintegration by USP <701>, and dissolution by USP <711> in a validated medium. The terminal product is a hard capsule for oral administration; if gelatin is replaced by HPMC, residual moisture is maintained below 5.0% to avoid shell crosslinking.

When a sachet-based oral granule product is specified, the granulation regime is shifted from high-shear binder addition to fluid-bed top-spray agglomeration because the sachet requires free-flowing, low-friable granules with a narrow particle-size distribution. A representative formulation for oral granules contains API 10.0 wt%, mannitol 44.0 wt%, maltodextrin 25.0 wt%, pregelatinized starch 12.0 wt%, povidone K30 3.0 wt%, citric acid 1.0 wt%, sucralose 0.2 wt%, colloidal silicon dioxide 0.3 wt%, and a species-appropriate flavour 4.5 wt%. The blend is agglomerated in a top-spray fluid-bed with inlet air temperature 60–75 °C, product temperature 28–34 °C, spray rate 10–30 g/min/kg, and atomising air pressure 1.0–2.0 bar. Drying continues to a final loss-on-drying of 1.0–2.0%, and the dried granules are screened to a D50 of 180–350 µm. Nozzle blockage and overwetting are controlled by limiting binder solution viscosity below 150 mPa·s and by continuous monitoring of product bed moisture.

Granule blends for sachets are filled by auger or volumetric filler into aluminium-foil laminate sachets. Fill weight variation is controlled gravimetrically, and seal integrity is tested by a validated method under ASTM F88/F88M or an equivalent compression-seal test. Content uniformity is evaluated on the filled sachets, and dissolution of the constituted product is assessed by USP <711> when the granules are intended for reconstitution. The terminal product is an oral granule in unit-dose sachets, with labelled storage protected from moisture and heat.

Low-Dose Tablet Production Requires Wet Granulation and Pre-Blend Deagglomeration

Content uniformity risk increases when the API fraction falls below 5 wt% of the core. In such cases, dry direct compression of dinotefuran is replaced by a wet granulation route with geometric pre-blending. A low-dose tablet formulation may contain API 2.0 wt%, lactose monohydrate 72.5 wt%, microcrystalline cellulose 18.0 wt%, povidone K30 3.0 wt%, croscarmellose sodium 3.0 wt%, and magnesium stearate 1.5 wt%. The API is first deagglomerated through a 250 µm screen and pre-blended with a portion of lactose in a tumble blender before high-shear granulation. The granulation endpoint is controlled by power consumption or wet mass consistency, followed by wet milling through a 1.0 mm screen and fluid-bed drying at inlet air 55–65 °C to 1.5–2.5% LOD. Dried granules are milled again and blended with extragranular croscarmellose sodium and magnesium stearate before compression.

On a rotary press, the low-dose tablets are compressed at 8–16 kN main compression force, with hardness and friability monitored every 5 minutes during the run. Uniformity of dosage units is tested by USP <905>; stratified blend sampling follows the principles of the FDA Powder Blend and Finished Dosage Units guidance. Dissolution is tested by USP <711>; residual solvents and elemental impurities are controlled by USP <467> and ICH Q3D. The terminal product is a film-coated low-dose oral tablet, in which the granulation route provides lower segregation risk than direct compression under high-speed tableting conditions.

When Dinotefuran Is Dissolved as an Aqueous Injectable, pH and Headspace Oxygen Must Be Mapped

An aqueous injectable solution is prepared by dissolving dinotefuran in Water for Injection, with pH adjusted to 5.0–6.5 using citrate or acetate buffer at 5–20 mM. Sodium chloride is added to target 270–330 mOsm/kg osmolality. The active concentration is governed by the approved product specification and is not fixed by a public monograph; published data for this specific injectable configuration is limited. The solution is sparged with nitrogen to reduce dissolved oxygen, then passed through a 0.22 µm PVDF or PES filter for sterilising-grade filtration. If terminal moist-heat sterilisation is used, it is run at 121 °C for 15 min; however, this route must be justified by thermal stability data for the finished formulation, because nitroguanidine hydrolysis can occur under alkaline conditions and at pH above 8.0. Bulk solution hold time is typically limited to 24 h at 2–8 °C when aseptic filtration is used without terminal sterilisation.

The filled solution is tested for sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, visible particulates by USP <790>, and pH by USP <791>. Container closure integrity is maintained in Type I glass vials with rubber stoppers under nitrogen headspace; extractables and leachables are assessed under 21 CFR 211.94. The terminal product is a sterile aqueous injection for parenteral administration, with the operational boundary that strong oxidising agents and alkaline admixtures are incompatible.

Lyophilised Injectable Cake Formation and Residual Moisture Control

Freeze-drying of dinotefuran requires the selection of bulking agents that produce a mechanically stable cake and permit reconstitution. A lyophilisation formulation may be prepared with API 15.0 wt% of total solids, mannitol 70.0 wt%, trehalose dihydrate 10.0 wt%, and a low-strength phosphate buffer 5.0 wt%. The solution is filled into Type I glass vials and freeze-dried using a cycle that freezes the product at −40 °C for 2 h, conducts primary drying at shelf temperature −20 °C to −10 °C with chamber pressure 80–150 mTorr for 20–30 h, and completes secondary drying at 25–35 °C for 6–12 h until residual moisture is ≤2.0% by USP <921> Karl Fischer titration. Collapse and meltback are prevented by maintaining product temperature below the collapse temperature of the formulation and by controlling chamber pressure within the mapped cycle envelope.

Lyophilised product is tested for sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, and reconstitution time. The terminal product is a sterile lyophilised cake for parenteral administration after reconstitution with a suitable diluent. This presentation is used only when aqueous solution stability is inadequate; published data for dinotefuran lyophilisation is limited, so cycle design must be verified for each vial load and fill volume.